Letters by company
Kkr-p-d
3 letters discussing KKR-P-D. Everything written about it on this site is on its ticker page.
- Greenhaven Road Capital Q4 2025 Greenhaven Road Capital groups Lifecore and Vistry as transformations whose operating progress has yet to be reflected in their valuations. It argues that fears around Burford, PAR, Cellebrite and KKR are overstated, while Hagerty’s State Farm rollout, operating leverage and marketplace expansion support its investment case. Q4 2025 BUR $772MCLBT $2.9BHGTY $4.8B
- Dodge & Cox Stock Fund Stock Fund Investment Commentary Dodge & Cox Stock Fund established positions in Visa, Thermo Fisher Scientific, and KKR after AI and macro concerns depressed shares of businesses it views as durable franchises. The fund retained conviction in Fidelity National Information Services, Fiserv, and Charter Communications, arguing that valuation declines overstate their long-term risks. second quarter of 2026 KKR-P-D TMO $246BV $696B
- Greenhaven Road Capital Main Fund Q2 Greenhaven Road Capital is reducing concentration, adding near-term catalysts and taking profits more readily while retaining its focus on advantaged businesses. It argues that Burford’s protein litigation, Hagerty’s insurer partnerships, Cellebrite’s Genesis launch, Lifecore’s strategic process and Kingsway’s search-model buildout can close valuation gaps. second quarter 2026 ANAB $1.4BBUR $772MCLBT $2.9B
